Ibuprofen Versus Indomethacin Following Emergent Cerclage Placement
Launched by WOMAN'S · Jan 22, 2021
Trial Information
Current as of July 22, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Viable, singleton pregnancy
- • ≥ 18 years old
- • Gestational age 16 weeks 0/7 days - 23 week 6/7 days (inclusive)
- • Intact membranes at time of enrollment
- • Planning to deliver at Woman's Hospital
- • Exam or ultrasound indicated cerclage placement
- Exclusion Criteria:
- • Contraindication to treatments (i.e. ibuprofen or indomethacin)
- • Unwilling to be randomized to treatment
- • Prophylactic cerclage placement
- • Temperature greater than 100.4
- • Known major fetal congenital anomaly
- • Prior cerclage placement during the current pregnancy
- • Recent (within 7 days) receipt of ibuprofen or indomethacin
About Woman's
Woman's is a leading healthcare organization dedicated to advancing women's health through innovative research and clinical trials. With a strong emphasis on delivering evidence-based solutions, Woman's focuses on a wide range of health issues specific to women, including reproductive health, maternal wellness, and chronic conditions. Committed to improving patient outcomes, Woman's collaborates with a diverse team of healthcare professionals and researchers to conduct rigorous clinical trials that prioritize safety, efficacy, and the unique needs of women. Through its pioneering efforts, Woman's aims to enhance the understanding of women's health and contribute to the development of new therapies and interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baton Rouge, Louisiana, United States
Patients applied
Trial Officials
Pamela Simmons, DO
Principal Investigator
Woman's Hospital, Louisiana
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials